Taysha Gene Therapies Inc Corporate Update Call Transcript
Welcome to the Taysha Gene Therapeutics -- Therapies GAN Program Update and 2023 Corporate Outlook Conference Call. (Operator Instructions). As a reminder, this webcast is being recorded today, January 31, 2023.
I will now turn the call over to Dr. Kimberly Lee, Chief Corporate Affairs Officer. Please go ahead.
Thank you, Sherry. Good afternoon, and welcome to Taysha's GAN Program Update and 2023 Corporate Outlook Conference Call.
Earlier today, Taysha issued a press release providing an update on the TSHA-120 program in giant axonal neuropathy or GAN, and corporate outlook for 2023. A copy of this press release is available on the company's website and through our SEC filings. On this call, we will review the regulatory feedback from FDA on our giant axonal's neuropathy program, discuss next steps for it and provide a corporate overview for 2023.
Joining me on today's call are Sean Nolan, Taysha's CEO; and Sukumar Nagendran, President and Head of R&D.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |